Large B-cell Lymphoma Clinical Trials

31 recruiting

Large B-cell Lymphoma Trials at a Glance

103 actively recruiting trials for large b-cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 2 with 60 trials, with the heaviest enrollment activity in New York, Duarte, and Houston. Lead sponsors running large b-cell lymphoma studies include City of Hope Medical Center, M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Browse large b-cell lymphoma trials by phase

Treatments under study

About Large B-cell Lymphoma Clinical Trials

Looking for clinical trials for Large B-cell Lymphoma? There are currently 31 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Large B-cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Large B-cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 103 trials

Recruiting
Phase 2

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell Lymphoma+12 more
National Cancer Institute (NCI)120 enrolled82 locationsNCT06649812
Recruiting
Phase 1

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
National Cancer Institute (NCI)47 enrolled54 locationsNCT04609046
Recruiting
Phase 1

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
National Cancer Institute (NCI)30 enrolled8 locationsNCT06015880
Recruiting
Phase 2

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Large B-cell Lymphoma
M.D. Anderson Cancer Center10 enrolled1 locationNCT07316010
Recruiting
Phase 1

Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.

Large B-Cell Lymphoma (LBCL)
Tel-Aviv Sourasky Medical Center12 enrolled1 locationNCT07361224
Recruiting
Phase 2

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRefractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+5 more
City of Hope Medical Center43 enrolled3 locationsNCT07365306
Recruiting
Phase 3

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

Large B-cell Lymphoma
AstraZeneca420 enrolled62 locationsNCT07215585
Recruiting
Phase 1

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center37 enrolled1 locationNCT06859008
Recruiting
Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic LeukemiaRecurrent LymphomaRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic80 enrolled4 locationsNCT03418038
Recruiting
Phase 1

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV InfectionRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+11 more
AIDS Malignancy Consortium20 enrolled6 locationsNCT05077527
Recruiting
Phase 1

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma+3 more
National Cancer Institute (NCI)32 enrolled9 locationsNCT05272384
Recruiting

Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma

Large B-Cell Lymphoma (LBCL)
N.N. Alexandrov National Cancer Centre76 enrolled1 locationNCT07524816
Recruiting
Phase 1

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive
Baylor College of Medicine90 enrolled2 locationsNCT06176690
Recruiting
Phase 1

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Large B-cell Lymphoma
Washington University School of Medicine24 enrolled1 locationNCT07052305
Recruiting
Phase 2

CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Large B-Cell Lymphoma (LBCL)
Zhejiang University40 enrolled1 locationNCT04661020
Recruiting
Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 2

Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym

Large B-cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute28 enrolled1 locationNCT06760156
Recruiting
Phase 1

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

LymphomaLeukemiaHodgkin Disease+4 more
Medical College of Wisconsin42 enrolled1 locationNCT05544968
Recruiting
Phase 2

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Large B-cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute27 enrolled1 locationNCT06104592
Recruiting
Phase 3

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed240 enrolled41 locationsNCT07409428